157 related articles for article (PubMed ID: 8320025)
21. Excretion of clofazimine in human milk in leprosy patients.
Venkatesan K; Mathur A; Girdhar A; Girdhar BK
Lepr Rev; 1997 Sep; 68(3):242-6. PubMed ID: 9364825
[TBL] [Abstract][Full Text] [Related]
22. Leprosy - an overview of clinical features, diagnosis, and treatment.
Fischer M
J Dtsch Dermatol Ges; 2017 Aug; 15(8):801-827. PubMed ID: 28763601
[TBL] [Abstract][Full Text] [Related]
23. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
Kumar A; Girdhar A; Girdhar BK
Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
[TBL] [Abstract][Full Text] [Related]
24. Production of transforming growth factor-beta 1 (TGF-beta1) by blood monocytes from patients with different clinical forms of leprosy.
Goulart IM; Mineo JR; Foss NT
Clin Exp Immunol; 2000 Dec; 122(3):330-4. PubMed ID: 11122237
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide levels in patients with erythema nodosum leprosum.
Vieira JL; Valente Mdo S
Ther Drug Monit; 2009 Oct; 31(5):602-3. PubMed ID: 19704404
[TBL] [Abstract][Full Text] [Related]
26. Annular vesiculobullous eruptions in type 2 reaction in borderline lepromatous leprosy: a case report.
Kar HK; Raina A; Sharma PK; Bhardwaj M
Indian J Lepr; 2009; 81(4):205-8. PubMed ID: 20704077
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous ulceration as a presenting feature of type 1 lepra reaction: A case report.
Hegde P; Jaiswal D; Shetty VM; Pai K; Rao R
Trop Doct; 2022 Apr; 52(2):354-356. PubMed ID: 35006027
[TBL] [Abstract][Full Text] [Related]
28. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions.
Silva EA; Iyer A; Ura S; Lauris JR; Naafs B; Das PK; Vilani-Moreno F
Trop Med Int Health; 2007 Dec; 12(12):1450-8. PubMed ID: 18076551
[TBL] [Abstract][Full Text] [Related]
29. A study of leprosy reactions in a tertiary hospital in Delhi.
Sharma N; Koranne RV; Mendiratta V; Sharma RC
J Dermatol; 2004 Nov; 31(11):898-903. PubMed ID: 15729862
[TBL] [Abstract][Full Text] [Related]
30. Reactive perforating leprosy, erythema multiforme-like reactions, sweet's syndrome-like reactions as atypical clinical manifestations of Type 2 leprosy reaction.
Gunawan H; Yogya Y; Hafinah R; Marsella R; Ermawaty D; Suwarsa O
Int J Mycobacteriol; 2018; 7(1):97-100. PubMed ID: 29516895
[TBL] [Abstract][Full Text] [Related]
31. Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum.
Schmitz V; Prata RB; Barbosa MG; Mendes MA; Brandão SS; Amadeu TP; Rodrigues LS; Ferreira H; Costa Fda M; Dos Santos JB; Pacheco Fdos S; Machado Ade M; Nery JA; Hacker Mde A; Sales AM; Pinheiro RO; Sarno EN
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004955. PubMed ID: 27556927
[TBL] [Abstract][Full Text] [Related]
32. Occurrence and management of leprosy reaction in China in 2005.
Shen J; Liu M; Zhou M; Wengzhong L
Lepr Rev; 2009 Jun; 80(2):164-9. PubMed ID: 19743620
[TBL] [Abstract][Full Text] [Related]
33. Effect of oral zinc supplementation on the cell mediated immunity in lepromatous leprosy.
el-Shafei MM; Kamal AA; Soliman H; el Shayeb F; Abdel Baqui MS; Faragalla S; Sabry MK
J Egypt Public Health Assoc; 1988; 63(5-6):311-36. PubMed ID: 2979949
[No Abstract] [Full Text] [Related]
34. Increased serum circulatory levels of interleukin 17F in type 1 reactions of leprosy.
Chaitanya S; Lavania M; Turankar RP; Karri SR; Sengupta U
J Clin Immunol; 2012 Dec; 32(6):1415-20. PubMed ID: 22847545
[TBL] [Abstract][Full Text] [Related]
35. Chromoblastomycosis in a case of borderline lepromatous leprosy with recurrent type II lepra reaction.
Apte G; Gedam JR; Poojary S; Nagpur NG; Pai VV; Ganapathi R
Lepr Rev; 2011 Sep; 82(3):310-5. PubMed ID: 22125940
[No Abstract] [Full Text] [Related]
36. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
de Carsalade GY; Achirafi A; Flageul B
Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
[TBL] [Abstract][Full Text] [Related]
37. Increased chitotriosidase activity in serum of leprosy patients: association with bacillary leprosy.
Iyer A; van Eijk M; Silva E; Hatta M; Faber W; Aerts JM; Das PK
Clin Immunol; 2009 Jun; 131(3):501-9. PubMed ID: 19307157
[TBL] [Abstract][Full Text] [Related]
38. Chemoimmunotherapy: its relevance in contemporary context.
Sehgal VN; Jain S
Int J Dermatol; 1994 Oct; 33(10):753-4. PubMed ID: 8002151
[No Abstract] [Full Text] [Related]
39. A new therapeutic approach to type II leprosy reaction.
Welsh O; Gómez M; Mancias C; Ibarra-Leal S; Millikan LE
Int J Dermatol; 1999 Dec; 38(12):931-3. PubMed ID: 10632777
[TBL] [Abstract][Full Text] [Related]
40. [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy].
Rodríguez G; Pinto R; López F; Gómez Y
Biomedica; 2009 Mar; 29(1):18-24. PubMed ID: 19753835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
